Jam3 promotes migration and suppresses apoptosis of renal carcinoma cell lines

Li,Xudong; Yin,Aiping; Zhang,Wenjing; Zhao,Fei; Lv,Jia; Lv,Jing; Sun,Jiping

doi:10.3892/ijmm.2018.3854

Jam3 promotes migration and suppresses apoptosis of renal carcinoma cell lines

Authors:
- Xudong Li
- Aiping Yin
- Wenjing Zhang
- Fei Zhao
- Jia Lv
- Jing Lv
- Jiping Sun
View Affiliations

Affiliations: Department of Nephrology and Urinary Surgery, The First Affiliated Hospital of Medical College, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China, Department of Nephrology and Urinary Surgery, The First Affiliated Hospital of Medical College, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China, Department of Gynaecology and Obstetrics, The First Affiliated Hospital of Medical College, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China
Published online on: September 4, 2018 https://doi.org/10.3892/ijmm.2018.3854
Pages: 2923-2929

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

As a common type of renal cancer, renal cell carcinoma (RCC) has a high annual mortality rate. The incidence of RCC has been increasing in China and worldwide. A large number cases of RCC are diagnosed at late stages, often with local and/or systematic metastasis. Surgical resection of RCC is only suitable for a small number of patients with early stage tumors, and thus, novel therapeutic methods are required. Junctional adhesion molecule 3 (Jam3) is a member of the junctional adhesion molecule family, which has been linked to epithelial and cancer cell proliferation. The present study investigated whether the Jam3 gene affected RCC growth via proliferation and apoptosis. The expression and biological function of Jam3 in renal carcinoma cells was investigated. The mRNA and protein levels of Jam3 were examined by reverse transcription‑polymerase chain reaction and western blot analyses. The role of Jam3 in the migration and apoptosis of renal carcinoma cells was determined using small interfering RNA, wound‑healing assays, flow cytometry, and cell migration assays. In the cell migration assays, E‑cadherin, N‑cadherin, integrin β1, and matrix metalloproteinase (MMP)‑2 proteins were detected by western blot analysis. It was shown that the expression of Jam3 was significantly elevated in human renal carcinoma cells compared with that in renal tubular epithelial cells. The knockdown of Jam3 inhibited renal carcinoma cell migration and promoted renal carcinoma cell apoptosis. It also increased the protein levels of E‑cadherin and reduced the protein levels of N‑cadherin, integrin β1 and MMP‑2. The inhibition of Jam3 promoted migration and suppressed apoptosis of renal carcinoma cells via regulation of the expression of E‑cadherin, N‑cadherin, integrin β1 and MMP‑2. Therefore, Jam3 was suggested as a novel target gene for the diagnosis and treatment of RCC.

View Figures

View References

1	Hirbod-Mobarakeh A, Gordan HA, Zahiri Z, Mirshahvalad M, Hosseinverdi S, Rini BI and Rezaei N: Specific immunotherapy in renal cancer: A systematic review. Ther Adv Urol. 9:45–58. 2017. View Article : Google Scholar : PubMed/NCBI
2	Turajlic S, Larkin J and Swanton C: SnapShot: Renal cell carcinoma. Cell. 163:1556–1556.e1. 2015. View Article : Google Scholar : PubMed/NCBI
3	Ling S, Nheu L and Komesaroff PA: Cell adhesion molecules as pharmaceutical target in atherosclerosis. Mini Rev Med Chem. 12:175–183. 2012. View Article : Google Scholar
4	Mazza C, Escudier B and Albiges L: Nivolumab in renal cell carcinoma: Latest evidence and clinical potential. Ther Adv Med Oncol. 9:171–181. 2017. View Article : Google Scholar : PubMed/NCBI
5	Thakor P, Song W, Subramanian RB, Thakkar VR, Vesey DA and Gobe GC: Maslinic acid inhibits proliferation of renal cell carcinoma cell lines and suppresses angiogenesis of endothelial cells. J Kidney Cancer VHL. 4:16–24. 2017. View Article : Google Scholar : PubMed/NCBI
6	Heng DY: The next 10 years: Challenges for the future and overcoming resistance to targeted therapies for renal cell carcinoma. Can Urol Assoc J. 10(11-12 Suppl 7): S256–S258. 2016. View Article : Google Scholar
7	Lim SH, Hwang IG, Ji JH, Oh SY, Yi JH, Lim DH, Lim HY, Lee SJ and Park SH: Intrinsic resistance to sunitinib in patients with metastatic renal cell carcinoma. Asia Pac J Clin Oncol. 13:61–67. 2017. View Article : Google Scholar
8	Santoso S, Sachs UJ, Kroll H, Linder M, Ruf A, Preissner KT and Chavakis T: The junctional adhesion molecule 3 (JAM-3) on human platelets is a counterreceptor for the leukocyte integrin Mac-1. J Exp Med. 196:679–691. 2002. View Article : Google Scholar : PubMed/NCBI
9	Galkina E and Ley K: Vascular adhesion molecules inatherosclerosis. Arterioscler Thromb Vasc Biol. 27:2292–2301. 2007. View Article : Google Scholar : PubMed/NCBI
10	Yin A, Zhang Q, Kong X, Jia L, Yang Z, Meng L, Li L, Wang X, Qiao Y, Lu N, et al: JAM3 methylation status as a biomarker for diagnosis of preneoplastic and neoplastic lesions of the cervix. Oncotarget. 6:44373–44387. 2015. View Article : Google Scholar : PubMed/NCBI
11	Gurzu S, Silveanu C, Fetyko A, Butiurca V, Kovacs Z and Jung I: Systematic review of the old and new concepts in the epithelial-mesenchymal transition of colorectal cancer. World J Gastroenterolog. 22:6764–6775. 2016. View Article : Google Scholar
12	Song Y, Wang L, Yang F, Wu X, Duan Q and Gong Z: Increased expressions of integrin subunit β1, β2 and β3 in patients with acute infection. Int J Med Sci. 12:639–643. 2015. View Article : Google Scholar :
13	Zheng B, Zhu H, Gu D, Pan X, Qian L, Xue B, Yang D, Zhou J and Shan Y: MiRNA-30a-mediated autophagy inhibition sensitizes renal cell carcinoma cells to sorafenib. Biochem Biophys Res Commun. 459:234–239. 2015. View Article : Google Scholar : PubMed/NCBI
14	Zheng B, Mao JH, Qian L, Zhu H, Gu DH, Pan XD, Yi F and Ji DM: Pre-clinical evaluation of AZD-2014, a novelmTORC1/2 dual inhibitor, against renal cell carcinoma. Cancer Lett. 357:468–475. 2015. View Article : Google Scholar
15	Zheng B, Mao JH, Li XQ, Qian L, Zhu H, Gu DH and Pan XD: Overexpression of DNA-PKcs in renal cell carcinomaregulates mTORC2 activation, HIF-2alpha expression and cell proliferation. Sci Rep. 6:294152016. View Article : Google Scholar
16	Wu D, Ding J, Wang L, Pan H, Zhou Z, Zhou J and Qu P: microRNA-125b inhibits cell migration and invasion bytargeting matrix metallopeptidase 13 in bladder cancer. Oncol Lett. 5:829–834. 2013. View Article : Google Scholar : PubMed/NCBI
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2^−ΔΔ^CT method. Methods. 25:402–408. 2001. View Article : Google Scholar
18	Mook OR, Frederiks WM and Van Noorden CJ: The role of gelatinases in colorectal cancer progression and metastasis. Biochim Biophysica Acta. 1705:69–89. 2004.
19	Su NW, Wu SH, Chi CW, Liu CJ, Tsai TH and Chen YJ: Metronomic cordycepin therapy prolongs survival of oral cancer-bearing mice and inhibits epithelial-mesenchymal transition. Molecules. 22:E6292017. View Article : Google Scholar : PubMed/NCBI
20	Matsubara M and Bissell MJ: Inhibitors of Rho kinase (ROCK) signaling revert the malignant phenotype of breast cancer cells in 3D context. Oncotarge. 7:31602–31622. 2016. View Article : Google Scholar
21	Moroz A, Delella FK, Lacorte LM, Deffune E and Felisbino SL: Fibronectin induces MMP2 expression in human prostate cancer cells. Biochem Biophys Res Commun. 430:1319–1321. 2013. View Article : Google Scholar
22	Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, et al: Pazopanib versus sunitinibin metastatic renal-cell carcinoma. N Engl J Med. 369:722–731. 2013. View Article : Google Scholar : PubMed/NCBI
23	Cohen HT and McGovern FJ: Renal-cell carcinoma. N Engl J Med. 353:2477–2490. 2005. View Article : Google Scholar : PubMed/NCBI
24	Motzer RJ, Bander NH and Nanus DM: Renal-cell carcinoma. N Engl J Med. 335:865–875. 1996. View Article : Google Scholar : PubMed/NCBI
25	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
26	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
27	Fiori E, De Cesare A, Galati G, Bononi M, D'Andrea N, Barbarosos A, Izzo L and Bolognese A: Prognostic significanceof primary-tumor extension, stage and grade of nucleardifferentiation in patients with renal cell carcinoma. J Exp Clin Cancer Res. 21:229–232. 2002.PubMed/NCBI
28	Uygur MC, Usubütün A, Ozen H, Ayhan A and Kendi S: Prognosticfactors and the role of nephrectomy in metastatic renal cellcarcinoma. J Exp Clin Cancer Res. 18:397–401. 1999.PubMed/NCBI
29	Amato RJ: Chemotherapy for renal cell carcinoma. Semin Oncol. 27:177–186. 2000.PubMed/NCBI
30	Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS, Patard JJ, Mulders PF and Sinescu IC; European Association of Urology Guideline Group: EAU guidelines on renal cell carcinoma: The 2010 update. Eur Urol. 58:398–406. 2010. View Article : Google Scholar : PubMed/NCBI
31	Dutcher JP and Nanus D: Long-term survival of patients with sarcomatoid renal cell cancer treated with chemotherapy. Med Oncol. 28:1530–1533. 2011. View Article : Google Scholar
32	Hajjari M, Behmanesh M, Sadeghizadeh M and Zeinoddini M: Junctional adhesion molecules 2 and 3 may potentially be involved in progression of gastric adenocarcinoma tumors. Med Oncol. 30:3802013. View Article : Google Scholar : PubMed/NCBI
33	Vonlaufen A, Aurrand-Lions M, Pastor CM, Lamagna C, Hadengue A, Imhof BA and Frossard JL: The role of junctional adhesion molecule C (JAM-C) in acute pancreatitis. J Pathol. 209:540–548. 2006. View Article : Google Scholar : PubMed/NCBI
34	Phan RT and Dalla-Favera R: The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature. 432:635–639. 2004. View Article : Google Scholar : PubMed/NCBI
35	Ebnet K, Aurrand-Lions M, Kuhn A, Kiefer F, Butz S, Zander K, Meyer zu Brickwedde MK, Suzuki A, Imhof BA and Vestweber D: The junctional adhesion molecule (JAM) family members JAM-2 and JAM-3 associate with the cell polarity protein PAR-3: A possible role for JAMs in endothelial cell polarity. J Cell Sci. 116:3879–3891. 2003. View Article : Google Scholar : PubMed/NCBI
36	Ebnet K, Suzuki A, Ohno S and Vestweber D: Junctional adhesion molecules (JAMs): More molecules with dual functions. J Cell Sci. 117:19–29. 2004. View Article : Google Scholar
37	Li J, Ballif BA, Powelka AM, Dai J, Gygi SP and Hsu VW: Phosphorylation of ACAP1 by Akt regulates the stimulation-dependent recycling of integrin beta1 to control cell migration. Dev Cell. 9:663–673. 2005. View Article : Google Scholar : PubMed/NCBI
38	Dai J, Li J, Bos E, Porcionatto M, Premont RT, Bourgoin S, Peters PJ and Hsu VW: ACAP1 promotes endocytic recycling by recognizing recycling sorting signals. Dev Cell. 7:771–776. 2004. View Article : Google Scholar : PubMed/NCBI
39	Sato K, Shirai R, Hontani M, Shinooka R, Hasegawa A, Kichise T, Yamashita T, Yoshizawa H, Watanabe R, Matsuyama TA, et al: Potent vasoconstrictor kisspeptin-10 induces atherosclerotic plaque progression and instability: Reversal by its receptor GPR54 antagonist. J Am Heart Assoc. 6:e0057902017. View Article : Google Scholar : PubMed/NCBI